Press & Media

PlexBio Presents Multiplex Mutation Analysis for Cancer Management by πCode Technology at Molecular Med Tri-Con 2018


San Francisco, CA (February 14, 2018) – PlexBio Co., Ltd. presented scientific data on the development and use of a series of novel multiplex assays on the company’s IntelliplexTM instrument system at this week’s 25th Molecular Med Tri-Conference in San Francisco, CA. The work presented relies on the novel πCodeTM MicroDisc technology developed by PlexBio to create a menu of high complexity companion diagnostic tests (CDx) which can rapidly determine the status of a wide range of somatic gene mutations or gene rearrangements typically seen in various cancers. During the technical presentation, PlexBio’s Chief Operating Officer, Stuart M. Palmer, Ph.D., described the mutation analysis results obtained for the company’s multi-gene Lung Cancer Panel which is currently under development and addressed the obstacles and challenges of high complexity panel development in general.

CDx assays are useful tools in assessing susceptibility to various cancer treatments. The determination of somatic mutations in various oncogenes can be used to direct the therapeutic strategies in individual patients and has greatly enhanced cancer management. But as useful as this approach is, it can be hampered by the invasive and lengthy procedures needed to obtain tissue samples from the patient and cumbersome assay workflows needed to confirm the presence of multiple mutations. In order to address some of these obstacles, PlexBio developed the IntelliPlexTM system and the πCodeTM MicroDisc technology as tools for building assays which enable the capture and detection of multiple targets simultaneously in a single reaction well from a complex sample.

PlexBio currently offers a series of individual CDx kits for gene mutation and rearrangement assays including reagent kits for EGFR, KRAS, BRAF, NRAS, PIK3CA, ALK and ROS1 gene mutations and gene rearrangement assays. The PlexBio system offers sensitive and specific results and can serve first-line diagnostic requirements as well as subsequent testing needs. The system’s multiplexing advantages place it in the complexity space bounded at the low end by traditional single test methods and large NGS panels which may not be practical for recurrent monitoring applications.

About PlexBio Co., Ltd.: PlexBio Co., Ltd., established in May 2010, designs, develops and manufactures IVD products and instrumentation from its headquarters in Taipei, Taiwan and its affiliate location in Jiangsu Province, China. PlexBio has also established an Innovative Technology Center in South San Francisco, CA, USA. The company is a listed company at Taiwan emerging stock market. http://www.plexbio.com

 

 

Contact Information:
PlexBio, Co., Ltd.
Address: 6F-1, No. 351, Yangguang St., Neihu District, Taipei City 11491, Taiwan
Tel: +886-2-2627-5878
Fax: +886-2-2627-5979
E-mail: contact@plexbio.com